Patents by Inventor Adam Fogel

Adam Fogel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TGFB INHIBITORS AND USE THEREOF
    Publication number: 20230057012
    Abstract: Disclosed herein are novel inhibitors of TGF?1 activation with durable inhibitory effects. Methods directed to the selection of a suitable TGF? inhibitor for various disease conditions and patient populations are also provided.
    Type: Application
    Filed: January 11, 2021
    Publication date: February 23, 2023
    Inventors: Stefan Wawersik, Thomas Schurpf, Christopher Chapron, Sandeep Kumar, Adam Fogel
  • TGF-BETA INHIBITORS AND USE THEREOF
    Publication number: 20230050148
    Abstract: The present disclosure provides TGF? inhibitor therapy for treating immunosuppressive conditions, such as cancer. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: January 11, 2021
    Publication date: February 16, 2023
    Inventors: Ashish Kalra, Thomas Schurpf, Adam Fogel, Christopher Brueckner, Alan Buckler, Constance Martin, Si Tuen Lee-Hoeflich
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220363741
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 17, 2022
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, JR.
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11365245
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: June 21, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220064276
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 3, 2022
    Inventors: Thomas SCHURPF, Justin W. JACKSON, George CORICOR, Abhishek DATTA, Stefan WAWERSIK, Christopher LITTLEFIELD, Adam FOGEL, Caitlin STEIN, Julia McCREARY, Matthew SALOTTO, Frederick STREICH, JR.
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11214614
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: January 4, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20210047396
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: August 19, 2020
    Publication date: February 18, 2021
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich